Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Galcanezumab in Japanese Migraine Patients
NCT02959190Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2017
- Primary completion
- Aug 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of galcanezumab in migraine (6 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants Who Had Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) at 16 months. Started Feb 2017; status: completed.
02
Drugs
galcanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02959190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02959190.